CoChat

Prognostic Implication of Plasma Metabolites in Gastric Cancer

Open access

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

Gastric cancer (GC) typically carries a poor prognosis as it is often diagnosed at a late stage. Altered metabolism has been found to impact cancer outcomes and affect patients’ quality of life, and the role of metabolites in gastric cancer prognosis has not been sufficiently understood. We aimed to establish a prognostic prediction model for GC patients based on a metabolism-associated signature and identify the unique role of metabolites in the prognosis of GC. Thus, we conducted untargeted metabolomics to detect the plasma metabolites of 218 patients with gastric adenocarcinoma and explored the metabolites related to the survival of patients with gastric cancer. Firstly, we divided patients into two groups based on the cutoff value of the abundance of each of the 60 metabolites and compared the differences using Kaplan–Meier (K-M) survival analysis. As a result, 23 metabolites associated with gastric cancer survival were identified. To establish a risk score model, we performed LASSO regression and Cox regression analysis on the 60 metabolites and identified 8 metabolites as an independent prognostic factor. Furthermore, a nomogram incorporating clinical parameters and the metabolic signature was constructed to help individualize outcome predictions. The results of the ROC curve and nomogram plot showed good predictive performance of metabolic risk features. Finally, we performed pathway analysis on the 24 metabolites identified in the two parts, and the results indicated that purine metabolism and arachidonic acid metabolism play important roles in gastric cancer prognosis. Our study highlights the important role of metabolites in the progression of gastric cancer and newly identified metabolites could be potential biomarkers or therapeutic targets for gastric cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms241612774

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The flow chart summarizes the scheme performed to construct prognostic risk score signatures of gastric cancer.
Figure 1 The flow chart summarizes the scheme performed to construct prognostic risk score signatures of gastric cancer.CC BY · PubMed Central
Figure 2 Classification of Detected Plasma Metabolites.
Figure 2 Classification of Detected Plasma Metabolites.CC BY · PubMed Central
Figure 3 Metabolites Associated with the Survival of GC Patients. Two groups in the K-M survival analysis were divided according to the cutoff value of metabolites, and the survival time was compared using the log-rank test (the blue line represents group 1, and the red line represents group 2, FDR_p < 0.05).
Figure 3 Metabolites Associated with the Survival of GC Patients. Two groups in the K-M survival analysis were divided according to the cutoff value of metabolites, and the survival time was compared using the log-rank test (the blue line represents group 1, and the red line represents group 2, FDR_p < 0.05).CC BY · PubMed Central
Figure 4 (a) LASSO coefficient profiles of the 60 metabolites. Different colors lines represent different metabolites. (b) A coefficient profile plot was produced against the log (lambda) sequence in the LASSO model. The red dots in the figure represent target parameters for each lambda value. In the graph, there are two dashed lines representing special lambda values. The first line on the left corresponds to the lambda value that minimizes the mean squared error, while the other line represents a lambda value that differs from it by one standard deviation. The optimal parameter (lambda) was selected as the first black dotted line indicated.
Figure 4 (a) LASSO coefficient profiles of the 60 metabolites. Different colors lines represent different metabolites. (b) A coefficient profile plot was produced against the log (lambda) sequence in the LASSO model. The red dots in the figure represent target parameters for each lambda value. In the graph, there are two dashed lines representing special lambda values. The first line on the left corresponds to the lambda value that minimizes the mean squared error, while the other line represents a lambda value that differs from it by one standard deviation. The optimal parameter (lambda) was selected as the first black dotted line indicated.CC BY · PubMed Central
Figure 5 The forest plot of the Cox regression analysis indicated eight metabolites associated with the survival status of GC patients.
Figure 5 The forest plot of the Cox regression analysis indicated eight metabolites associated with the survival status of GC patients.CC BY · PubMed Central
Figure 6 (a) The optimal cut-off points of risk scores identified by X-tile software (version 3.6, Yale University, New Haven, CT, USA); (b) GC patients were divided into three risk score levels (low, medium, and high) based on the cut-off value. The blue color represents low-risk for poor prognosis, gray represents medium-risk, and pink represents high-risk for poor prognosis; (c) K-M survival analysis shows a significant difference in survival time among the three groups (The blue line represents the low-risk group, the gray line represents the moderate-risk group, and the pink line represents the high-risk group. p < 0.05); (d) (A–F) Violin plots show that surgery and TNM stage are significant with the association of metabolite risk scores.
Figure 6 (a) The optimal cut-off points of risk scores identified by X-tile software (version 3.6, Yale University, New Haven, CT, USA); (b) GC patients were divided into three risk score levels (low, medium, and high) based on the cut-off value. The blue color represents low-risk for poor prognosis, gray represents medium-risk, and pink represents high-risk for poor prognosis; (c) K-M survival analysis shows a significant difference in survival time among the three groups (The blue line represents the low-risk group, the gray line represents the moderate-risk group, and the pink line represents the high-risk group. p < 0.05); (d) (A–F) Violin plots show that surgery and TNM stage are significant with the association of metabolite risk scores.CC BY · PubMed Central
Figure 7 ROC Analysis of the Prognostic Metabolites Signature. The AUC of 1-year, 3-year, and 5-year survival curves show good sensitivity and specificity predictive performance of the metabolite risk scores.
Figure 7 ROC Analysis of the Prognostic Metabolites Signature. The AUC of 1-year, 3-year, and 5-year survival curves show good sensitivity and specificity predictive performance of the metabolite risk scores.CC BY · PubMed Central
Figure 8 The nomogram was constructed based on five independent prognostic factors.
Figure 8 The nomogram was constructed based on five independent prognostic factors.CC BY · PubMed Central
Figure 9 The calibration plots for the internal validation of the nomogram predicting 1-year (a), 3-year (b), and 5-year (c) survival probability. The y axis represents the nomogram actual survival, and the x axis represents the predicted survival. The diagonal dotted line represents a perfect prediction by an ideal model. The red line represents the performance of the nomogram. The blue bars indicate the confidence intervals.
Figure 9 The calibration plots for the internal validation of the nomogram predicting 1-year (a), 3-year (b), and 5-year (c) survival probability. The y axis represents the nomogram actual survival, and the x axis represents the predicted survival. The diagonal dotted line represents a perfect prediction by an ideal model. The red line represents the performance of the nomogram. The blue bars indicate the confidence intervals.CC BY · PubMed Central
Figure 10 Analysis of gastric cancer survival-related metabolite pathways.
Figure 10 Analysis of gastric cancer survival-related metabolite pathways.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

See all 17

Metadata

Authors
Cao, K., Lyu, Y., Chen, J., He, C., Lyu, X., Zhang, Y., Chen, L., Jiang, Y., Xiang, J., Liu, B., & Wu, C.
Affiliations
Fujian Medical University (CN)
Corresponding author
Wu, Chuancheng
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2023-08-14
Volume
24
Issue
16
Pages
12774
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4385805803
Cited by
16
References
54
Citations by year
2026: 4 · 2025: 5 · 2024: 5 · 2023: 2
FWCI
1.42
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Fujian Natural Science Foundation (2015J01673, 2017J01811)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords
gastric cancer, plasma metabolites, prognostic factors, untargeted metabolomics, metabolic signatures, survival prediction, risk scoring, nomogram, purine metabolism, arachidonic acid metabolism, gastric adenocarcinoma
MeSH terms
Humans, Prognosis, Quality of Life, Stomach Neoplasms, Nomograms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognostic Implication of Plasma Metabolites in Gastric Cancer. https://app.cochat.ai/papers/10.3390/ijms241612774
The paper
Cao, K., Lyu, Y., Chen, J., He, C., Lyu, X., Zhang, Y., Chen, L., Jiang, Y., Xiang, J., Liu, B., & Wu, C. (2023). Prognostic Implication of Plasma Metabolites in Gastric Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241612774

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.